# US 2022/0031792 A1 · Composition and method to help manage the lingering effects of covid-19 in patients after recovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031792 A1
- Document ID: US20220031792A1
- Status: Published application
- Kind: A1
- Application number: 17/347,859
- Filed: 2021-06-15
- Published: 2022-02-03
- Earliest claimed: 2020-07-28
- Assignees: NutriScience Innovations LLC
- Applicants: NutriScience Innovations LLC
- Inventors: Michael Lelah
- Web page: https://patentgrep.com/patent/US20220031792A1

## CPC

- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

The present disclosure relates to compositions and methods for helping to manage the lingering symptoms and effects of COVID-19 after recovery. Specifically, the present disclosure relates to sustained release dietary and nutritional supplement compositions and methods to provide ongoing support and symptom management for individuals exposed to SARS-CoV-2 who contacted COVID-19 and later recovered but continue to experience after-effects or lingering symptoms. Specifically, the composition is based on a sustained release ashwagandha extract, alone in a therapeutically effective amount, or in combination with other ingredients.

## Claims

### Claim 1

A sustained release dietary supplement composition comprising active ingredients formulated in a therapeutic effective amount to manage lingering symptoms in patients recovering from COVID-19 due to SARS-CoV-2 virus.

### Claim 2 (depends on 1)

The sustained release dietary supplement composition according to claim 1, wherein the active ingredient comprises a botanical adaptogen.

### Claim 3 (depends on 2)

The sustained release dietary supplement composition according to claim 2, wherein the botanical adaptogen is ashwagandha extract.

### Claim 4 (depends on 3)

The sustained release dietary supplement composition according to claim 3, wherein the ashwagandha extract containing at least 35% withanolide glycosides.

### Claim 5 (depends on 4)

The sustained release dietary supplement composition according to claim 4, wherein the composition contains a range of about 60 to 240 mg ashwagandha extract containing at least 35% withanolide glycosides.

### Claim 6 (depends on 4)

The sustained release dietary supplement composition according to claim 4, wherein composition is 120 mg ashwagandha extract containing at least 35% withanolide glycosides.

### Claim 7 (depends on 1)

The sustained release dietary supplement composition according to claim 1, wherein the active ingredients are ashwagandha extract and other natural product actives combined to manage the lingering symptoms.

### Claim 8 (depends on 1)

The sustained release dietary supplement composition according to claim 1, wherein the composition may be a capsule, tablet, softgels, gummy, candy, beverage or food, or other such sustained release oral delivery system for dietary supplements.

### Claim 9

A sustained release tablet or capsule comprising an ashwagandha extract formulated in a therapeutic effective amount to manage lingering symptoms in patients recovering from COVID-19 due to the SARS-CoV-2 virus.

### Claim 10 (depends on 9)

The sustained release tablet or capsule according to claim 9, wherein the tablet or capsule contains a range of about 60 to 240 mg ashwagandha extract containing at least 35% withanolide glycosides.

### Claim 11 (depends on 9)

The sustained release tablet or capsule according to claim 9, wherein the tablet or capsule contains 120 mg ashwagandha extract containing at least 35% withanolide glycosides.

### Claim 12

A method for supporting symptom management, including after-effects and/or lingering symptoms of COVID-19, the method comprising the steps of administering to the patient in need thereof a therapeutically effective amount of a sustained release nutritional supplement comprising ashwagandha and compositions containing ashwagandha.
